| Literature DB >> 31991830 |
Irina Fierascu1, Ioana Catalina Fierascu2,3, Roxana Ioana Brazdis1, Anda Maria Baroi1, Toma Fistos1, Radu Claudiu Fierascu1.
Abstract
Phytosynthesized nanoparticles represent a continuously increasing field of research, with numerous studies published each year. However, with the emerging interest in this area, the quality of the published works is also continuously increasing, switching from routine antioxidant or antimicrobial studies on trivial microbial lines to antibiotic-resistant strains or antitumoral studies. However, this increasing interest has not been not reflected in the studies regarding the toxicological effects of nanoparticles (NPs); this should be a subject of greatest interest, as the increasing administration of NPs in general (and phytosynthesized NPs in particular) could lead to their accumulation in the environment (soil, water and living organisms). The present review aims to present the most recent findings in the application of phytosynthesized NPs as antimicrobial and antitumoral agents, as well as the results regarding their toxicological potential.Entities:
Keywords: antimicrobial; antitumoral; phytosynthesized nanoparticles; toxicology
Year: 2020 PMID: 31991830 PMCID: PMC7040630 DOI: 10.3390/ma13030574
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Published papers on the topic of the current review. (a) Studies on the general topic of nanoparticles phytosynthesis and (b) studies on the selected topics, both published in 2019. The relatively high number of papers published on the topic “toxicity” was due to the overlapping of other applications (antimicrobial and antitumoral) and due to keywords/abstract description provided by the authors.
Figure 2Antimicrobial mechanism of nanoparticles (adapted from [9,10,11,12]).
Antimicrobial potential of phytosynthesized silver nanoparticles (as presented in studies published in 2019).
| Extract Used | NPs Characteristics | Microbial Lines | Antimicrobial Effect | Ref. |
|---|---|---|---|---|
| Spherical, 50–60 nm | Gram-positive ( | IZ = 24/16 mm | [ | |
| Spherical, 7.85–26.11 nm | Gram-negative ( | IE = 52%–56.6%/45.9%–56.1%/48.2%–58.4%/42.2%–46.4%/39.6%/47.4%/67.1%–88.77%/80%–88.3%/88.2%–94.7% at 200 mg/L, | [ | |
| Spherical, cubic, 30–90 nm | Gram-positive ( | IZ = 28/28/29/18/24 mm | [ | |
| Spherical, 30–70 nm | Gram-positive ( | MIC = 400/100 mg/L | [ | |
| Spherical, 33.93 nm (average diameter) | MIC = 125/250/62.5/500/500/250/500/250/500/250 mg/L | [ | ||
| Spherical, 1–23 nm |
| IZ = 18.5/15.3 mm at 7.5 μg | [ | |
| Spherical, 5–10 nm |
| MIC = 25/25/100 mg/L | [ | |
| Mainly spherical, 10–45 nm |
| Visible inhibition zone (not quantified) | [ | |
| Spherical, oblongated, 50 nm |
| IZ = 1.5 mm at 334.11 mg/L | [ | |
| Spherical, 25–73 nm |
| MIC = 0.25–1 ( | [ | |
| Spherical, 35–55 nm | Inhibition of the tested strains, no quantification provided | [ | ||
| Spherical, 11.9 nm |
| IZ = 10/11/12/14 mm at 200 μL | [ | |
| Spherical, 10–50 nm |
| IZ = 17.4/19.2 mm at 100 mg/L | [ | |
| Spherical, 22.7 nm |
| MIC = 1.5/2.5/0.5/1.5 mg/L | [ | |
| Heterogenous morphology, 18–25 nm |
| MIC = 15/14/18/17 mg/L | [ | |
| Spherical, 5.76–19 nm |
| IZ = 14/17/15/16 mm at 25 μg | [ | |
| Pseudospherical, 2–80 nm |
| MIC = 0.325 mg/L at a 6:4 nitrate/extract ratio | [ | |
| Spherical, 77.8–85.3 nm |
| IZ = 11.5/8.33/8.67/8.5/9/8.8 mm at 10 μL | [ | |
| Spheroidal, 5–20 nm |
| MIC = 32/16–64 mg/L | [ | |
| Spherical, 5–30 nm |
| MIC = 12.5/25 mg/L | [ | |
| Spherical, polygonal, triangular, 32–62 nm (pH-dependent) |
| MIC = 0.09–0.34/0.19–0.54/0.99–2.74/0.15–0.41 mg/mL (dependent on metal source) | [ | |
| Spherical, 25.28 nm |
| MIC = 125/62.5/125/31.25/62.5/250 mg/L | [ | |
| Spherical, 16,92 nm |
| IZ = 20/36/19.5/ absent at 0.03 mg | [ | |
| Spherical, 29 nm |
| 92%/89%/69% inhibition after 6 days, respectively, MIC = 200 mg/L | [ | |
| Spherical, 12–20/3.2–12 nm |
| IZ = 11.03–13.8/13.9–15.8 mm ( | [ | |
| Spherical, 6.52–25.24 nm |
| IZ = 11.73/10.20 mm | [ | |
| Spherical, 3–15 nm |
| IZ = 14.2/13.6/15.9/14.1 mm | [ | |
| Spherical, 80–150 nm |
| IZ = 24.87/26.93 at 5% | [ | |
| Spherical, 6–41 nm |
| IZ = 16/14 mm | [ | |
| Spherical, 10–22 nm |
| Absence of colonies at 50 mg/L | [ | |
| Spherical, 17.51 nm |
| MIC90 = 0.04/0.04/0.04/0.04/0.04/0.09/0.02 mg/L | [ | |
| Spherical 20–40 nm |
| IZ = 39.8–49.2 mm at 64 mg/mL | [ | |
| Spherical, oval, hexagonal and Triangular, 12–80 nm |
| IZ = 10.2/10.5/10.8/9.24 at 60 μg | [ | |
| Spherical, 8–50 nm |
| IZ = 17/19/17/19.3/17.7/18 mm at 100 mg/L | [ |
Where: ac.—acetone; aq.—aqueous; eth.—ethanol; IE—inhibitory effect (percentage cell death); isoprop.—isopropyl alcohol; IZ—inhibition zone; meth.—methanol; MIC—minimum inhibitory concentration; and MIC90—minimum inhibitory concentration required to inhibit the growth of 90% of organisms.
Figure 3Factors influencing the morphological characteristics of silver nanoparticles and, consequently, their antimicrobial properties.
Antimicrobial potential of other phytosynthesized nanoparticles (as presented in studies published in 2019).
| NPs | Extract Used | NPs Characteristics | Microbial Lines | Antimicrobial Effect | Ref. |
|---|---|---|---|---|---|
| Au NPs | Mix of | Spherical, with irregular forms, 44.96 nm |
| >4 mm inhibition zones, superior for Gram-negative bacteria | [ |
| Au NPs | Spherical, few triangular, 7 nm (1 mM metal salt precursor)/55 nm (2 mM) |
| IZ = 10.2–12.1 mm, MIC = 16.75–21.50 mg/L | [ | |
| Au NPs | Spherical, 40–45 nm |
| IZ = 33–38 mm at 64 mg/mL (against | [ | |
| Au NPs | Spherical, 10–60 nm |
| IZ = 24/10 mm at 40 μL | [ | |
| Au NPs | Triangular, spherical, 16 nm |
| IZ = 21 mm at 100 mg/L | [ | |
| Cu NPs | Spherical, 45–50 nm |
| MFC = 2–8 mg/mL, MBC = 4–8 mg/mL (Gram-negative), 2–8 mg/mL (Gram-positive) | [ | |
| Fe NPs | Irregular shapes, 29.5–51.1 nm |
| IZ = 11/11/14/15/17/16 mm at 2 mg/mL, MIC = 0.5 mg/mL | [ | |
| Ti NPs | Spherical, 22 nm |
| MFC = 8–16 mg/mL, MBC = 4 mg/mL | [ | |
| Se NPs | Spherical, 15–40 nm |
| MBC = 33.17–97.5 mg/L, MFC = 10.67–38.17 mg/L | [ | |
| ZnO NPs | Spherical, 70–75 nm |
| IZ = 17/15/17/15 mm at 100 μg | [ | |
| ZnO NPs | Spherical/spherical and rod-shaped, 15–20/20–30 nm | IZ = 6/5 ( | [ | ||
| ZnO NPs | Spherical, 90 nm |
| IZ = 26/24 mm at 50 μg/well | [ | |
| ZnO NPs | Spherical, hexagonal, 26.57 nm |
| 20% inhibition at 100 mg/L | [ | |
| ZnO NPs | Hexagonal, triangular, 20–30 nm |
| MIC = 7.8–125 mg/L, best results for | [ | |
| ZnO NPs | Hexagonal, 40 nm |
| IZ = 10.83/8.43/8.92/6.5 at 1000 mg/L | [ | |
| ZnO NPs | Semi-spherical, 38–49 nm |
| IZ = 22.7/19.3 at 200 mg/L | [ | |
| ZnO NPs | Hexagonal, cubic, 50 nm |
| IZ = 20.33/20.33/20/18.33/16/17 mm at 100 mg/L | [ | |
| ZnO NPs | Spherical, hexagonal, 20–30 nm |
| MIC = 1200 mg/L | [ | |
| Fe2O3 NPs | Spherical, 20 nm |
| MIC = 31.25–125 mg/L | [ | |
| Fe3O4 NPs | Dendrimer shaped, with branches, 1–150 nm |
| IZ = 12.16–13.16 at 0.1 M metallic salt precursor, MIC = 50/12.5/50 mg/L | [ | |
| MgO NPs | Flower shaped, 68.02 nm |
| IZ = 9/8 mm at 30 mg/L, MIC = 256 mg/L, MBC = 256/1024 mg/L | [ | |
| MgO NPs | Flower shaped, 8.8 nm | IZ = 5.1 cm at 16 mg/L | [ | ||
| NiO NPs | Spherical, 18.6 nm |
| IZ = 10 mm ( | [ | |
| CoO NPs | 21 nm |
| MIC = 21.875/87.5/175/43.75/175/21.875/43.75/21.875/175/21.875 mg/L | [ | |
| Ag/TiO2 NPs | Spherical, 17 nm |
| IZ = 64/64/128/64 mg/L | [ | |
| Au/Ag NPs | Multiple morphologies (spherical, triangular, hexagonal, rod-shaped, etc.) 30–50 nm |
| IZ = 14.66/13.66/11/9.33 mm | [ | |
| Au/Ag NPs | Clusters, spherical |
| IZ = 14/13 mm at 50 μL | [ | |
| Au, Ag, Au/Ag NPs | Spherical, rod-shaped aggregates, 16–70/18–80/44–55 nm |
| IE = 36%–76%/52%–94%/53%–85% at 80 mg/L | [ | |
| Au, ZnO and Au/ZnO core-shell NPs | Spherical, 20–50 nm |
| Complete inhibition at 500/750 mg/L after 3 h | [ | |
| Fe3O4, Cu, Fe3O4/Cu NPs | Spherical, 25/37/62 nm |
| MIC = 0.01/0.05/0.02 (Cu)/0.01/0.04/0.03 (composite) | [ |
Where: aq.—aqueous; Au NPs—gold nanoparticles; Cu NPs—copper nanoparticles; CoO NPs—cobalt oxide nanoparticles; CuO NPs—copper oxide nanoparticles; Fe NPs—iron nanoparticles; Fe2O3 NPs—iron(III) oxide nanoparticles; Fe3O4 NPs—iron(II, III) oxide nanoparticles; IE—inhibitory effect (percentage cell death); IZ—inhibition zone; MBC—minimum bactericidal concentration; MFC—minimum fungicidal concentration; MgO NPs—magnesium oxide nanoparticles; NiO NPs—nickel oxide nanoparticles MIC—minimum inhibitory concentration; MIC90—minimum inhibitory concentration required to inhibit the growth of 90% of organisms; Se NPs—selenium nanoparticles; Ti NPs—titanium nanoparticles; and ZnO NPs—zinc oxide nanoparticles.
Figure 4Antitumoral mechanism of nanoparticles (adapted from [73,81]).
Antitumoral potential of phytosynthesized silver and gold nanoparticles (as presented in studies published in 2019).
| NPs | Extract Used | NPs Characteristics | Cell Lines | Main Findings | Ref. |
|---|---|---|---|---|---|
| Ag NPs | Spherical, 7.85–26.11 nm | A549 | MTS assay—CD = 55.6%/44.9%/43.5% | [ | |
| Ag NPs | Spherical, cubic, 30–90 nm | Cow RBC | Lysis effect: 1.75%/100% | [ | |
| Ag NPs | Spherical, 33.93 nm | MCF7 | MTT assay—EC50 = 6.25 mg/L | [ | |
| Ag NPs | Spherical, 35–55 nm | MCF7 | MTT assay—EC50 = 2.49 mg/L | [ | |
| Ag NPs | Spherical, 10–50 nm | MCF7 | MTT assay—EC50 = 23 mg/L | [ | |
| Ag NPs | Spherical, 5.76–19 nm | MCF7, MG-63 | MTT assay—EC50 = 90/70 mg/L after 24 h | [ | |
| Ag NPs | Spherical, 25.28 nm | A549 | MTT assay—EC50 = 12.5 mg/L | [ | |
| Ag NPs | Spherical, 16,92 nm | A549 | MTT assay—EC50 = 86.23 mg/L after 24 h | [ | |
| Ag NPs | Spherical, 3–15 nm | SiHa | MTT assay—CV = approx. 10% after 24 h at 500 mg/L | [ | |
| Ag NPs | Spherical, 10–22 nm | MCF7, HeLa | CV = 48%/38% after 96 h, at 50 mg/L | [ | |
| Ag NPs | Spherical, oval, hexagonal, triangular, 12–80 nm | LNCaP | MTT assay—CV = approx. 38% after 24 h at 100 mg/L | [ | |
| Ag NPs | Spherical, 8–50 nm | A549 | MTT assay—EC50 = 113.25 mg/L at 24 h | [ | |
| Ag NPs | Spherical, 50 nm | HeLa | LDH assay—Ctx = 58% after 24 h at 150 mg/L | [ | |
| Ag NPs | Spherical, 5–50 nm | HCT-116 | MTT assay—EC50 = 60 mg/L | [ | |
| Ag NPs | Spherical, 8.83/11.24 nm | MCF7, 5637 | EC50 = 6.32/17.32 (MCF7) 5.54/27.89 (5637) mg/L | [ | |
| Ag NPs | Polygonal, 15–73 nm | MCF7 | MTT assay—EC50 = 20 mg/L after 24 h | [ | |
| Ag NPs | Spherical, 17–19 nm | MCF7 | MTT assay—EC50 = 188 mg/L | [ | |
| Ag NPs | Spherical, 100–150 nm | MCF7 | MTT assay—EC50 = 10 g/L for 24 h | [ | |
| Ag NPs | Spherical, 28.8 nm | HeLa | MTT assay—EC50 = 5.27 mg/L after 24 h | [ | |
| Ag NPs | Spherical, 24 nm | HCT-116, HeLa, A549 | MTT assay—EC50 = 8/16/29 mg/L | [ | |
| Ag NPs | Spherical, 76 nm | MDA-MB-231, MDA-MB-453, AGS | MTT assay—EC50 = 33.521/36.25/7.14 mM/L | [ | |
| Ag NPs | Spherical, 12.62–41.44 nm | MDA-MB-231 | WST-1 method, EC50 = 138.8 mg/L | [ | |
| Ag NPs | Spherical, 40 nm | Antimitotic activity, chromosomal aberrations; MTT assay—EC50 = 134.67/118.5 mg/L | [ | ||
| Ag, Au NPs | Spherical, 12.22/13.45 (Au), 21.96/22.08 (Ag) nm | Antimitotic activity, chromosomal aberrations | [ | ||
| Au NPs | Triangular, spherical, 16 nm | HT-29 | MTT assay—EC50 = 22.62 mg/L | [ | |
| Au NPs | Mix of | Spherical, with irregular forms, 44.96 nm | MCF7, TCT-116, HCepG-2 | MTT assay—EC50 = 45.5/37.2/40.6 μL | [ |
| Au NPs | Spherical, 10–60 nm | MCF7 | MTT assay—EC50 = 6 mg/L | [ | |
| Au NPs | Spherical, few triangular, 7 nm (1 mM metal salt precursor)/55 nm (2 mM) | AGS | Annexin V/Propidium Iodide staining assay CV > 70% at 24 h, for both types of NPs at 200 mg/L | [ | |
| Au NPs | Spherical, triangular, hexagonal, 10–40 nm | HeLa | WST-1 method, CV = approx. 50% at 400 mg/L | [ | |
| Au NPs | Spherical, oval-shaped, 40–50 nm | A549 | MTT assay—EC50 = 15 mg/L | [ | |
| Au NPs | Spheres, stars, 8.7/99 nm | AGS, HeLa, HepG2, HT-29 | Cytotoxic towards all lines, MTT assay—EC50 = 127.1/81.8 μM (HepG2) | [ | |
| Au NPs | Pseudospherical trigonal, rod-shaped, 20 nm | A549, MDA-MB 468, HepG2 | MTT assay, EC50 = 143/157.9/70.2 μg/L | [ | |
| Au NPs | Hexagonal, spherical, oval, triangular, 12–80 nm | PANC-1 | MTT assay—CV = approx. 25% after 48 h at 30 mg/L | [ | |
| Au NPs | Spherical, 30–50 nm | HeLa | MTT assay—EC50 = 10 mg/L after 24 h | [ | |
| Au NPs | Spherical, 20 nm | B16 | MTT assay—EC50 = 10 mg/L after 24 h | [ | |
| Au NPs | Spherical, 2–10 nm | HeLa, MCF7, A549, H1299 | MTT assay—EC50 = 200/~180/~220/~350 mg/L after 24 h | [ | |
| Au NPs | Spherical, 130 nm | A549 | MTT assay—EC50 = 50 mg/L after 24 h | [ | |
| Au NPs | Spherical, triangular, hexagonal, 5–45 nm | MCF7 | MTT assay—CV = 20% after 48 h at 200 mg/L | [ |
Where: 5637—human bladder carcinoma cells; A549—human lung carcinoma cells; ac.—acetone; AGS—human gastric adenocarcinoma cells; aq.—aqueous; B16—murine tumor cells; CD—cell death; Ctx = cytotoxicity; CV = cell viability; EC50—half maximal effective concentration; eth.—ethanol; H1299—human non-small cell lung carcinoma cells; HCepG-2—human hepatocellular carcinoma cells; HCT-116—colorectal cancer cells; HeLa—human cervical epithelioid carcinoma cells; HepG2—human hepatocyte carcinoma cells; HT-29—human colon cancer cells; LNCaP—prostate adenocarcinoma cells; MCF-7 breast adenocarcinoma cells; MDA-MB-231—Invasive ductal carcinoma cells (triple negative breast cancer); MDA-MB-453—human breast cancer cell line (non-triple negative breast cancer); MDA-MB 468—human breast cancer cells; meth.—methanol; MG-63—osteoblast cells; MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PANC-1—pancreatic cancer cells; RBC—red blood cells; SiHa—cervical cancer cells; TCT-116—human colon carcinoma cells; and WI 38—human lung fibroblast cells.
Antitumoral potential of other phytosynthesized nanoparticles (as presented in studies published in 2019).
| NPs | Extract Used | NPs Characteristics | Cell Lines | Main Findings | Ref. |
|---|---|---|---|---|---|
| ZnO NPs | Spherical, 70–75 nm | A549 | MTT assay—EC50 = 65 mg/L | [ | |
| ZnO NPs | Spherical, 90 nm | MCF7, HepG2, A549 | MTT assay—CV < 65% after 24 h, at 100 mg/L | [ | |
| ZnO NPs | Hexagonal, triangular, 20–30 nm | HepG2 | MTT assay—EC50 = 19.67 mg/L | [ | |
| ZnO NPs | Hexagonal, 40 nm | A549, HepG2 | MTT assay—EC50 = 383.05/329.67 mg/mL | [ | |
| ZnO NPs | Hexagonal, cubic, 50 nm | A549 | MTT assay—EC50 = 51.25 mg/L | [ | |
| ZnO NPs | Pseudo-spherical, 20–40 nm | MDA-MB-231, MCF7 | MTT assay—CV = 7/4% after 72 h at 500/100 mg/L | [ | |
| ZnO NPs | Spherical, 32.9 nm | WEHI 164 | MTT assay—EC50 = 212.5 mg/L | [ | |
| ZnO NPs | Spherical, 33.14–99.03 nm | HeLa | XTT assay—CV = 59.03% at 1000 mg/L | [ | |
| ZnO NPs | Rod-shaped, 1.39 nm | SiHa | MTT assay—EC50 = 35 mg/L | [ | |
| ZnO NPs | Hexagonal, 20–50 nm | HeLa | MTT assay—EC50 = 50 mg/L | [ | |
| ZnO NPs | Spherical, 12–24 nm | HCT-116 | MTT assay—EC50 = 20 mg/L | [ | |
| Fe2O3 NPs | Spherical, 20 nm | HepG2 | MTT assay—EC50 = 13.47 mg/L | [ | |
| Fe3O4 NPs | Spherical, <50 nm | A549 | MTT assay—CV approx. 40%, at 100 mg/L | [ | |
| Fe2O3, PbO NPs | Elliptical, spherical, 38 nm/Irregular, 23 nm | HepG2 | SRB method—CV = 20.88%/38.49% after 24 h at 200 mg/L | [ | |
| Fe NPs | Spherical, 31.84 nm | SW1353 | MTT assay—CV = 62% at 150 mg/L | [ | |
| CeO2 NPs | Spherical, 20 nm | MDA-MB-231 | MTT assay—CV = 41.47% after 48 h at 125 mg/L | [ | |
| CeO2 NPs | Spherical, 22 nm | MCF7 | MTT assay—CV = 38.67% after 72 h at 1000 mg/L | [ | |
| CeO2 NPs | Spherical, 10–15 nm | HT-29 | MTT assay—CV = 80% after 24 h at 800 mg/L | [ | |
| CoO NPs | 21 nm | HepG2 | MTT assay—EC50 = 31.4 mg/L | [ | |
| MgO NPs | Flower shaped, 68.02 nm | A549 | MTT assay—EC50 = 37.5 mg/L | [ | |
| NiO NPs | Spherical, 18.6 nm | Neuro2a | MTT assay—CV approx. 58% at 500 mg/L | [ | |
| Se NPs | Spherical, 50 nm | HepG2 | MTT assay—CV = 50% at 30 mg/L | [ | |
| ZnS NPs | Spherical, 8.35 nm | MCF7 | MTT assay—EC50 = 400 mg/L | [ | |
| CuO, ZnO, CuO/ZnO NPs | Spherical, star-like (for the composite), 16.25/75.22/3.54 nm | HeLa | MTT assay—CV = 63.64/44.05/39.94 after 48 h at 100 mg/L | [ | |
| Ag/TiO2 NPs | Spherical, 17 nm | MCF7 | MTT assay—CV approx. 45% after 24 h at 100 μM | [ | |
| Fe3O4/Au NPs | Core-shell, 6.08 nm | HT-29 | MTT assay—EC50 = 235 mg/L | [ |
Where: A549—human lung carcinoma cells; aq.—aqueous; CV = cell viability; EC50—half maximal effective concentration; H4IIE-luc—rat hepatocellular carcinoma; HCT-116—colorectal cancer cells; HeLa—human cervical epithelioid carcinoma cells; HepG2—human hepatocyte carcinoma cells; HT-29—human colon cancer cells; HuTu-80—human duodenal adenocarcinoma cells; MCF-7 breast adenocarcinoma cells; MDA-MB-231—Invasive ductal carcinoma cells (triple negative breast cancer); MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Neuro2a—fast-growing mouse neuroblastoma cells; SiHa—cervical cancer cells; SRB—sulforhodamine B; SW1353—human chondrosarcoma cells; WEHI 164—murine fibrosarcoma cells; and XTT—2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt.
Biocompatibility studies regarding phytosynthesized nanoparticles (as presented in studies published in 2019).
| NPs | NPs Characteristics | Cell Lines | Main Findings | Ref. |
|---|---|---|---|---|
| Ag NPs | Spherical, 33.93 nm | VERO | MTT assay—EC50 = 12.5 mg/L | [ |
| Ag NPs | Spherical, 35–55 nm | VERO | MTT assay—EC50 = 5.3 mg/L | [ |
| Ag NPs | Spherical, 10–50 nm | HEK-293 | MTT assay—EC50 = 23 mg/L | [ |
| Ag NPs | Spherical, 22.7 nm | WI-38 | CV = 90% at 100 mg/L | [ |
| Ag NPs | Spherical, 5.76–19 nm | 3T3 | MTT assay—EC50 = 110 mg/L after 24 h | [ |
| Ag NPs | Spherical 20–40 nm | HUVEC | MTT assay—EC50 = 760 mg/L | [ |
| Ag NPs | Spherical, 8.83/11.24 nm | HaCaT | EC50 = 490/300 mg/L | [ |
| Ag NPs | Spherical, 28.8 nm | HEK-293 | MTT assay—EC50 = 1844 mg/L after 24 h | [ |
| Ag NPs | Spherical, 24 nm | hPBLs | MTT—CV = 70% at 80 mg/L | [ |
| Au NPs | Spherical, 10–60 nm | PBMC | MTT assay—EC50 = 600 mg/L | [ |
| Au NPs | Spherical, triangular, hexagonal, 10–40 nm | HEK-293 | WST-1 method, CV > 95% at 500 mg/L | [ |
| Au NPs | Spherical, 2–10 nm | HEK-293 | MTT assay—CV > 80% at 400 mg/L after 24 h | [ |
| Au NPs | Spherical, triangular, hexagonal, 5–45 nm | MCF-10A | MTT assay—CV = not affected after 48 h at 200 mg/L | [ |
| ZnO NPs | Hexagonal, triangular, 20–30 nm | RBC | MTT assay—EC50 > 200 mg/L | [ |
| ZnO NPs | Hexagonal, 20–50 nm | HEK-293 | MTT assay—CV = 76% at 200 mg/L | [ |
| ZnO NPs | Spherical, 12–24 nm | VERO | MTT assay—EC50 = 30 mg/L | [ |
| Fe2O3 NPs | Spherical, 20 nm | RBC | MTT assay—EC50 > 200 mg/L | [ |
| Fe2O3, PbO NPs | Elliptical, spherical, 38 nm/Irregular, 23 nm | RBC | SRB method—CV = 59%/50.3% after 24 h at 400 mg/mL | [ |
| Fe NPs | Spherical, 31.84 nm | VERO | MTT assay—CV = 80% at 150 mg/L | [ |
| Se NPs | Spherical, 15–40 nm | N2a | MTT assay—EC50 = 127.28 mg/L | [ |
| Se NPs | Spherical, 50 nm | VERO | MTT assay—CV not affected after 48 h at 60 mg/L | [ |
| Cu NPs | Spherical, 45–50 nm | HUVEC | MTT assay—CV > 85% after 48 h at 1000 mg/L | [ |
| CeO2 NPs | Spherical, 20 nm | HUVEC | MTT assay—CV = 87.67% after 72 h at 1000 mg/L | [ |
| CeO2 NPs | Spherical, 23 nm | Lymphocytes | MTT assay—CV = 99.38% at 2.5 mg/L | [ |
| CoO NPs | 21 nm | Human macrophages and erythrocytes | MTT assay—EC50 > 200 mg/L | [ |
| MgO NPs | Flower shaped, 68.02 nm | PBMC | MTT assay—CV > 95% after 24 h at 100 mg/L | [ |
| Au, ZnO and Au/ZnO core-shell NPs | Spherical, 20–50 nm | Mouse fibroblast cells | MTT assay—CV = >80%/>50%/>70% at 250 mg/L | [ |
| Fe3O4/Au NPs | Core-shell, 6.08 nm | 3T3 | MTT assay—EC50 > 500 mg/L | [ |
Where: 3T3—normal skin fibroblast cells; CV = cell viability; EC50—half maximal effective concentration; HaCaT—spontaneously transformed aneuploid immortal keratinocyte cell line from adult human skin; HEK-293—human embryonic kidney cells; hPBLs—human peripheral blood lymphocyte cultures; HUVEC—human umbilical vein endothelial cells; MCF-10A—non-tumorigenic epithelial cells; MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; N2a—Mus musculus neuroblastoma cells; PBMC—peripheral blood mononuclear cells; RBC—red blood cells; SRB—sulforhodamine B; VERO—monkey kidney epithelial cells; WI-38—diploid human fibroblasts lung tissue cells.
Toxicological studies regarding phytosynthesized nanoparticles (as presented in studies published in 2019).
| NPs | Plant Material | NPs Characteristics | Test Organisms | Main Findings | Ref. |
|---|---|---|---|---|---|
| Ag NPs | Spherical, 5–10 nm | Mice injected with different doses (10–200 μg) of NPs | No hemorrhage and edema observed in experimental mice up to 100 μg | [ | |
| Ag NPs | Spherical, 10–50 nm | No mortality recorded at to 250 μg/L, affection of the swimming behavior at 250 μg/L (erratic swimming, migration to the bottom of the beaker or the water surface). | [ | ||
| Ag NPs | Spherical, 28.8 nm | No toxicity recorded | [ | ||
| Ag NPs | Spherical, 12.62–41.44 nm | Acute oral toxicity evaluated on Wistar rats administered 500–2000 mg/kg NP doses | LD50 > 2000 mg/kg, no significant difference for mean organ-to-body weight ratio except in the liver and in all hematological parameters except WBC and hematocrit; no significant difference for serum electrolytes. total protein, urea, GGT, AST, ALP, ALT, albumin, bilirubin; changes in creatinine, urea, and cholesterol levels. | [ | |
| Ag NPs | Spherical, 10–50 nm | [ | |||
| Au NPs | Triangular, spherical, 16 nm | No mortality or morphology variations after 96 h at 100 mg/L | [ | ||
| Au NPs | Spherical, 1–1.5 nm | Wistar male rats treated with 2, 5, 10 mg/kg released into the lungs | Increased amount of Au in serum and heart, LDH and CK-MB activities, cardiovascular injuries | [ | |
| ZnO NPs | Hexagonal, triangular, 20–30 nm | LC50 = 26.34 mg/L | [ | ||
| Zn NPs | Spherical, 30–80 nm | Oral acute and subacute toxicity in male NMRI mice administered NPs by oral gavage for 14 days | LC50 = 5.5 g/kg (non-toxic); low oral toxicity at 1, 2 and 3 g/kg after 14 days; sub-acute effects—changes in the body weight, hematological parameters, no toxicological effects at 1 g/kg | [ | |
| Fe2O3 NPs | Spherical, 20 nm | LC50 = 32.41 mg/L | [ | ||
| CoO NPs | 21 nm | LC50 = 18.12 mg/L | [ | ||
| CeO2 NPs | Spherical, 23 nm | Female Sprague-Dawley rats orally administered doses of 200/400 mg/kg body weight for 14 days | No effect on serum biochemistry, except for creatine phosphokinase (significantly reduced) | [ |
Where: ALP—alkaline phosphatase; ALT—alanine aminotransferase; aq.—aqueous; AST—aspartate aminotransferase; CK-MB—creatine kinase-MB isoenzyme; GCT—ɣ-glutamyl transferase; LC50—half maximal lethal concentration; LDH—serum lactate dehydrogenase; meth.—methanol; N2a—Mus musculus neuroblastoma cells; WBC—white blood cells.
Figure 5Relevant findings of the in vivo toxicological studies using phytosynthesized nanoparticles; rodent studies are highlighted.